Cargando…

Tocilizumab in COVID-19 therapy: who benefits, and how?

Detalles Bibliográficos
Autores principales:	Neumann, Avidan U, Goekkaya, Mehmet, Dorgham, Karim, Traidl-Hoffmann, Claudia, Gorochov, Guy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298010/ https://www.ncbi.nlm.nih.gov/pubmed/34303430 http://dx.doi.org/10.1016/S0140-6736(21)01427-6

Ejemplares similares

Tocilizumab in COVID-19 therapy: who benefits, and how?
por: Yang, Chengliang, et al.
Publicado: (2021)

Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply
por: Horby, Peter, et al.
Publicado: (2021)

Considering Personalized Interferon Beta Therapy for COVID-19
por: Dorgham, Karim, et al.
Publicado: (2021)

Longitudinal Cytokine Profiling in Patients with Severe COVID-19 on Extracorporeal Membrane Oxygenation and Hemoadsorption
por: Lebreton, Guillaume, et al.
Publicado: (2021)

WHO prequalified tocilizumab and vaccine boosters against COVID-19
por: Rahimi, Farid, et al.
Publicado: (2022)

Distinct cytokine profiles associated with COVID-19 severity and mortality
por: Dorgham, Karim, et al.
Publicado: (2021)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Tocilizumab in COVID-19: finding the optimal route and dose
por: Jain, Siddharth, et al.
Publicado: (2020)

Successful treatment of a critical COVID-19 patient with tocilizumab
por: Tsao, Shih-Ming, et al.
Publicado: (2021)

Heart-Kidney Transplanted patient affected by COVID-19 pneumonia treated with tocilizumab on top of immunosuppressive maintenance therapy
por: Ammirati, Enrico, et al.
Publicado: (2020)

First, Do No Harm: Caution Against Use of Tocilizumab in COVID-19
por: Mastroianni, Fiore
Publicado: (2020)

Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Identification of the Single Immunodominant Region of the Native Human CC Chemokine Receptor 6 Recognized by Mouse Monoclonal Antibodies
por: Dorgham, Karim, et al.
Publicado: (2016)

Combining 16S Sequencing and qPCR Quantification Reveals Staphylococcus aureus Driven Bacterial Overgrowth in the Skin of Severe Atopic Dermatitis Patients
por: De Tomassi, Amedeo, et al.
Publicado: (2023)

Corticosteroid Plus Tocilizumab in COVID-19: When Two Is Better Than One
por: Kow, Chia Siang, et al.
Publicado: (2021)

Successful treatment of tocilizumab and ivermectin for a patient with ARDS due to COVID-19
por: Chuang, Tzu-Yi, et al.
Publicado: (2021)

Benchmarking MicrobIEM – a user-friendly tool for decontamination of microbiome sequencing data
por: Hülpüsch, Claudia, et al.
Publicado: (2023)

Prominent Plasmacytosis Following Intravenous Immunoglobulin Correlates with Clinical Improvement in Guillain-Barré Syndrome
por: Mori, Izumi, et al.
Publicado: (2008)

Questioning Tocilizumab Use in Hospitalized Patients With Coronavirus Disease 2019
por: Mombrun, Martin, et al.
Publicado: (2021)

Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytoma
por: Eberst, Lauriane, et al.
Publicado: (2020)

Impact of Interleukin-6 Receptor Blockade With Tocilizumab on Cardiac Injury in Patients With COVID-19: A Retrospective Cohort Study
por: Weber, Brittany N, et al.
Publicado: (2021)

“Efficacy of tocilizumab in treatment of COVID-19 pneumonia: A case–control study from a tertiary care hospital”
por: Barthwal, M. S., et al.
Publicado: (2023)

Necrotizing fasciitis with slow progression in a patient with rheumatoid arthritis receiving tocilizumab
por: Goto, Kazuya, et al.
Publicado: (2022)

How medical students’ early workplace experience could benefit the NHS
por: Oyekwe, George Chukwuemeka, et al.
Publicado: (2021)

How interprofessional education could benefit the future of healthcare – medical students’ perspective
por: Choudhury, Regwaan Imtiaz, et al.
Publicado: (2020)

Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis
por: Leclercq, Mathilde, et al.
Publicado: (2023)

Potential Benefits of Tryptophan Metabolism to the Efficacy of Tocilizumab in COVID-19
por: Belladonna, Maria Laura, et al.
Publicado: (2020)

The WHO declares COVID-19 is no longer a public health emergency of international concern: benefits, challenges, and necessary precautions to come back to normal life
por: Sarker, Rapty, et al.
Publicado: (2023)

Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment
por: Masuccio, Fabio Giuseppe, et al.
Publicado: (2020)

How to follow-up a patient who received tocilizumab in severe COVID-19: a case report
por: Podlasin, Regina B., et al.
Publicado: (2020)

WHO COVID-19 therapeutic guidelines
por: Rochwerg, Bram, et al.
Publicado: (2021)

COVACTA trial raises questions about tocilizumab's benefit in COVID-19
por: Furlow, Bryant
Publicado: (2020)

Is There any Additional Benefit of Multiple Doses of Tocilizumab in COVID-19 Patients?
por: Mughal, Mohsin S, et al.
Publicado: (2020)

Where did all the retinal detachments go? Gathering insights into who did not attend during the first peak of COVID-19
por: Ramsden, Conor M., et al.
Publicado: (2021)

BENEFIT OF IRON THERAPY IN THE MANAGEMENT OF CHRONIC URTICARIA DUE TO NICKEL SENSITIVITY
por: Sharma, Ashimav Deb
Publicado: (2010)

How the Covid-19 pandemic affects our perspective on the medical treatment of acute appendicitis in children
por: Boleken, Mehmet Emin, et al.
Publicado: (2022)

Who should be prioritised for COVID-19 vaccines?
por: Hassan-Smith, Zaki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_381ea17g3kl2vndetnds7edg4q